GLOBAL BLOOD THERAPEUTICS Stock News

SOUTH SAN FRANCISCO, Calif., April 29, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2020 financial results on.

NEW YORK, April 29, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Global Blood.

Equities researchers at Stifel Nicolaus initiated coverage on shares of Global Blood Therapeutics (NASDAQ:GBT) in a research report issued on Monday, Marketbeat Ratings reports. The firm set a “buy�

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG (CRSP) yesterday. The company's shares closed last Tuesday at $52.52.

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG ( CRSP – Research Report ) yesterday. The company’s shares closed last Tuesday at $52.52. According to TipRanks.

Mirum Pharmaceuticals (NASDAQ: ]) has added Peter Radovich to its C-suite as its chief operating officer. Radovich was most recently executive vice

William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics (PTCT) today. The company's shares closed last Tuesday at $53.80. According

William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics ( PTCT – Research Report ) today. The company’s shares closed last Tuesday at $53.80. According to TipRanks.com , Pras

In a report released today, Matthew Harrison from Morgan Stanley initiated coverage with a Buy rating on Zentalis Pharmaceuticals (ZNTL). The company's

Adverum Biotechnologies (NASDAQ:ADVM) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs.Alector (NASDAQ:ALEC) initiated with Buy rating and $32 (21% upside) price target at

Global Blood Therapeutics initiated with a Buy at Stifel Stifel GBT NVS

Global Blood Therapeutics Inc (NASDAQ:GBT)’s stock price traded up 11.9% during mid-day trading on Friday . The stock traded as high as $81.54 and last traded at $80.29, 1,821,218 shares were traded

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Tricia Borga Suvari sold 4,080 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an aver

Nomura analyst Christopher Marai maintained a Buy rating on Prothena (PRTA) yesterday and set a price target of $19.00. The company's shares closed last

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Biogen (BIIB) with bullish